Page 335 - ATP-P 11th Ed

• Adverse reactions
• Nausea
Adverse reactions:
• Dry skin
• Tenderness
• Swelling
• Contact dermatitis
• Increased exudate (rare)
• Systemic reactions (rare)
Other notes:
• For external use only.
• Avoid eyes and mucosal membranes.
• If no improvement in 3 to 5 days, consider alternative therapy.
TMEP use:
• Epistaxis Protocol
• Ingrown Toenail Protocol

®
Narcan – See Naloxone HCl SECTION 3
®
Naloxone HCl (Narcan )
GROUNDING medication for personnel on flight status
Description: Narcotic antagonist
Indications: Known or suspected narcotic induced respiratory depression
• Have available when using Morphine
Adult dose: 0.4–2mg IV (repeat q2–3min/prn)
• Duration is 20 to 40 minutes (less than the duration of action of morphine). Repeat doses
may be necessary after 20 to 30 minutes.
Pediatric dose: 0.01mg/kg dose IM/IV/SQ q2–3min
• If initial dose does not result in clinical response, increase dose up to 0.1mg/kg.
• If no response after 10mg has been administered, diagnosis of narcotic-induced toxicity
should be questioned.
K9 Dose: 0.02–0.04mg/kg IV, IM, or SQ
Contraindications: Known allergy to medication
Pregnancy Category B
Side-effects: In narcotic dependent patient, withdrawal symptoms may be precipitated.
Adverse reactions: With higher than recommended doses:
• Nausea
• Vomiting
• Tachycardia

ATP-P Handbook 11th Edition 325